Wilmington, DE, United States of America

Hui-Fang Chang

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Astrazeneca Ab. Active years: 2007-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui-Fang Chang. Retrieved from https://idiyas.com/inventor/hui-fang-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 42.9

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 23(Granted Patents)

Company Filing History:

7 out of 1,534

Astrazeneca Ab

patents

Years Active: 2007-2010

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7842803 - Nicotinic acetylcholine receptor ligands 101 (2010-11-30),

2. 7514567 - Oxazolidinone nicotinic acetylcholine receptor agonists (2009-04-07),

3. 7465795 - Compounds and uses thereof (2008-12-16),

4. 7425556 - Compounds and uses thereof (2008-09-16),

5. 7417050 - Heterocyclic compounds (2008-08-26),

6. 7417049 - Furyl compounds (2008-08-26),

7. 7186836 - Thienyl compounds (2007-03-06),

Title: Hui-Fang Chang: Innovator in Pharmaceutical Chemistry

Introduction

Hui-Fang Chang is a prominent inventor based in Wilmington, Delaware, known for her significant contributions to pharmaceutical chemistry. With a total of seven patents to her name, she has made remarkable advancements in the field of nicotinic acetylcholine receptor ligands.

Latest Patents

Her latest patents include innovative compounds such as nicotinic acetylcholine receptor ligands of Formula I, which encompass diastereoisomers, enantiomers, and pharmaceutically-acceptable salts. These compounds are detailed in her specifications, along with methods of making and pharmaceutical compositions containing them. Another notable patent involves oxazolidinone nicotinic acetylcholine receptor agonists, which are defined by specific formulas and include pharmaceutical compositions and formulations. These inventions aim to treat various diseases and conditions, either alone or in combination with other therapeutically-active compounds.

Career Highlights

Hui-Fang Chang is currently employed at AstraZeneca AB, where she continues to push the boundaries of pharmaceutical research. Her work has been instrumental in developing new therapeutic options for patients.

Collaborations

Some of her notable coworkers include Eifion D. Phillips and Marc Chapdelaine, who contribute to her innovative projects and research endeavors.

Conclusion

Hui-Fang Chang's work exemplifies the spirit of innovation in pharmaceutical chemistry, and her patents reflect her dedication to improving healthcare through scientific advancements.

Profile summary based on public USPTO records.